SUBSCRIBE

Breaking News on Biopharmaceutical Development & Manufacturing

Top Headlines

Immunotherapy in the UK? National manufacturing site backed by GE

GE Healthcare has pledged its support and technology to a national £55m ($86m) Cell Therapy manufacturing centre in Stevenage, UK, set to launch in 2017.

UK Gov backs national immunotherapy centre

Biocon planning new biomanufacturing plant in India

Indian drugmaker and biosimilars pioneer Biocon has told the Chief Minister of Andhra Pradesh it intends to set up a new biomanufacturing plant.

Rouble trouble: Big Pharma exposure to Russian currency volatility limited

Big Pharma firms’ exposure to Russia’s volatile rouble is limited and planned manufacturing investments will go ahead according to observers.

Baxter exits vaccines business as it preps for biopharma spinout

Baxter has sold its pandemic flu portfolio and Vero cell technology to Nanotherapeutics in preparation for the launch of its haematology and oncology-based spinout company Baxalta. 

Singapore develops plan to support influx of biomanufacturing

Industry heavyweights and Singaporean development groups have unveiled a five-year roadmap to deal with the need for more employees in the fast-growing biologics manufacturing industry on the island.

Bruker to pay $2.4m to settle SEC charge of improper payments in China

Bruker Corp will pay $2.4m to settle US SEC charges that employees improperly funded Chinese officials' sightseeing trips to win analytical tech contracts at state labs.

Want to work for Pfizer? Get ready for ‘American Idol’ audition

Pfizer has revealed a unique way of hiring employees in Sweden it compares to “American Idol” auditions.

GPhA reaches compromise on thorny biosimilars substitution question

In the ongoing fight over whether US pharmacists will be allowed to prescribe biosimilars in place of their reference products, the Generic Pharmaceutical Association has agreed on “compromise legislation” with innovator manufacturers.

Spotlight

AstraZeneca shutting asthma drug plant as pipeline shifts to biologics

AstraZeneca shutting asthma drug plant as pipeline shifts to biologics

AstraZeneca has continued the Big Pharma trend away from small molecule blockbusters and towards a biologics-heavy pipeline,...

Increased dealmaking will launch stem cell therapies within 5 years

Report: Increased dealmaking will launch stem cell therapies within 5 years

Stem cell therapies are on the brink of breaking through into the mainstream drug market, according to...

Reports of Pierre Fabre's pharma death greatly exaggerated? Cancer mAb R&D to continue

Reports of Pierre Fabre's pharma death greatly exaggerated? Cancer mAb R&D to continue

Pierre Fabre has spared its biopharmaceutical research team from job cuts unveiled last night, signalling that high...

Biopharma's margins can withstand Capex increases after tech sector M&As, expert

Biopharma's margins can withstand Capex increases after tech sector M&As, expert

High margins mean biopharmas can absorb technology price increases after a year of supplier consolidation according to...

Indian company launches world’s first Humira biosimilar

Indian company launches world’s first Humira biosimilar

The first rival to AbbVie’s mega-blockbuster arthritis treatment Humira has hit the shelves in India, with Zydus...

Horizon Discovery enters crowded CHO cell line market

Horizon Discovery enters crowded CHO cell line market

Horizon Discovery Group announced Monday that its bioproduction division has shipped its first commercially available engineered CHO...

Key Industry Events

 

Access all events listing

Our events, Events from partners...

On demand Supplier Webinars

Biosimilars: developing, manufacturing and selling
William Reed Business Media
All supplier webinars